Anti-egfr antibodies and antibody drug conjugates
OwnerEdward B. Reilly, Andrew C. Phillips +3inventors
InventorsEdward B. Reilly, Andrew C. Phillips, Lorenzo Benatuil, Chung-Ming Hsieh, Jennifer Perez
Life of this patent
Estimating the term…
Abstract
The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
Claims5
An anti-human epidermal growth factor receptor (anti-hEGFR) antibody comprising
- a heavy chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 12, a heavy chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 11, and a heavy chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 20;
- and
- a light chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 28, a light chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 27, and a light chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 26,
- wherein the antibody is an IgG isotype.
An anti-human epidermal growth factor receptor (anti-hEGFR) antibody comprising
- a heavy chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 22, a heavy chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 3, and a heavy chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 21;
- and
- a light chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 31, a light chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 30, and a light chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 29,
- wherein the antibody is an IgG isotype.
A method for treating a subject having cancer, comprising administering an effective amount of an antibody drug conjugate (ADC) comprising an anti-EGFR antibody conjugated to at least one auristatin, wherein the anti-EGFR antibody is an IgG isotype;
- comprises a heavy chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 12, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 11, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 10;
- and comprises a light chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 8, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 7, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 6.
Dependencies are inferred from the claim text.